First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2015-12-10
Target enrollment:
Participant gender:
Summary
This is a phase I, single-arm, single-center, open-label, dose-escalation Study evaluating
the safety and efficacy of CT053PTSA in patients with Advanced Solid Tumors